HistoSonics gets Taiwan approval for its tumour-destroying ultrasound system as it pushes into Asia

HistoSonics has received regulatory approval from Taiwan’s Food and Drug Administration for its Edison Histotripsy System, a non-invasive cancer treatment device that uses focused ultrasound to destroy tumours without cutting, radiation, or thermal damage. The TFDA authorisation, announced on 18 May, marks a significant step in the company’s expansion into Asia and adds Taiwan to […] This story continues at The Next Web